All In Biotech

Drug Trial Radar · NCT01708590

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

Last checked: Nov 20, 2026Latest source record: Jan 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 661 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

661

Actual

Start

Aug 2012

Primary completion

May 2014

Study completion Aug 2015

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Oct 17, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.

Conditions

  • Psoriasis

Interventions

  • 210 mg brodalumabDrug

    210 mg brodalumab administered subcutaneous (SC)

  • 140 mg brodalumabDrug

    140 mg brodalumab administered subcutaneous (SC)

  • placeboDrug

    Placebo administered subcutaneous (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75 at Week 12Time frame: 0-12 weeks
  2. Percentage of Participants With Static Physician Global Assessment (sPGA) Score Success (Score of 0 or 1) at Week 12Time frame: 0 - 12 Weeks

Locations

78 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Encino, California

  • Research Site

    Los Angeles, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    San Ramon, California

  • Research Site

    Santa Monica, California

  • Research Site

    Alpharetta, Georgia

  • Research Site

    West Dundee, Illinois

  • Research Site

    Richmond, Kentucky

  • Research Site

    Columbia, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Fort Gratiot, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    Buffalo, New York

  • Research Site

    Forest Hills, New York

  • Research Site

    Rochester, New York

  • Research Site

    Stony Brook, New York

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Rapid City, South Dakota

  • Research Site

    Goodlettsville, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Arlington, Texas

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Surrey, British Columbia, Canada

  • Research Site

    Moncton, New Brunswick, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    Greater Sudbury, Ontario, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    North Bay, Ontario, Canada

  • Research Site

    Waterloo, Ontario, Canada

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.